COVID-19 trials registries data warehouse

 Return to trial list

Trial - EUCTR2020-002166-13-ES


Column Value
Trial registration number EUCTR2020-002166-13-ES
Full text link
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

First author
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Dr. Ramón Lleonart Bellfill / Dr. Xavier Corbella Virós - Dr. Ramón Lleonart Bellfill

Contact
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

rlleonart@bellvitgehospital.cat

Registration date
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

2020-07-22

Recruitment status
Last imported at : March 31, 2022, 3:46 p.m.
Source : EU Clinical Trials Register

Completed

Study design
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

RCT

Allocation
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Randomized

Design
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Parallel

Masking
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Open label

Center
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

multi-center

Study aim
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Treatment

Inclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

1-adult patients (18 years or older), both sexes 2-Sars-CoV-2 infection confirmed by PCR less than 4 days before randomization 3-hospitalized with a diagnosis of SARS-CoV-2 pneumonia 4-radiographic evidence of pulmonary infiltrates 5-grade 4 or 5 on the ordinal scale for the evaluation of the patient's clinical condition 6-pO2/FiO2 <380 7-men and women of childbearing age who have heterosexual relations must be agreement to use the safe method(s) of contraception 8-obtaining the informed consent of the patient or the legal representative. 1-pacientes adultos (18 años o más), de ambos sexos 2-infección por SARS-CoV-2 confirmada por PCR menos de 4 días antes de la aleatorización 3-hospitalizados con diagnóstico de neumonía por SARS-CoV-2 4-evidencia radiográfica de infiltrados pulmonares 5-grado 4 ó 5 en la escala ordinal para la evaluación del estado clínico del paciente 6-pO2/FiO2 <380 7-los hombres y mujeres en edad fértil que tienen relaciones heterosexuales deben estar de acuerdo en usar el método o métodos de anticoncepción seguros 8-obtención del consentimiento del paciente o representante legal.

Exclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

1-imminent death (life expectancy less than 72h) 2-known hypersensitivity or known adverse reactions to the study drug, or its metabolites or excipients of the formulation 3-invasive mechanical ventilation 4-participation in any other clinical trial 5- ALT or AST > 5 x ULN 6-creatinine clearance <50 mL/min using the Cockcroft-Gault formula for participants '18 years old [Cockcroft 1976] 7-patients with recent acute coronary syndrome (<1 month) 8-patients with a history of stroke 9-positive pregnancy test 10-pregnant or lactating woman 1-muerte inminente (expectativa de vida menos de 72h) 2-hipersensibilidad conocida o reacciones adversas conocidas al fármaco del estudio, o a sus metabolitos o a excipientes de la formulación 3-ventilación mecánica invasiva 4-participación en cualquier otro ensayo clínico 5- ALT o AST > 5 x ULN 6-eliminación de creatinina <50 mL/min utilizando la fórmula Cockcroft-Gault para participantes `18 años de edad [Cockcroft 1976] 7-pacientes con síndrome coronario agudo reciente (< 1 mes) 8-pacientes con antecedentes de accidente cerebrovascular 9-prueba de embarazo positiva 10-mujer embarazada o lactante

Number of arms
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

2

Funding
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Dr. Ramón Lleonart Bellfill / Dr. Xavier Corbella Virós

Inclusion age min
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

18

Inclusion age max
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

100

Countries
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Spain

Type of patients
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Moderate/severe disease at enrollment

Severity scale
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

4: Moderate/severe disease at enrollment

Total sample size
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

120

primary outcome
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Efficacy and safety will be evaluated 10 (±1) days after the start of treatment or at hospital discharge if before day 10: number of patients reaching grade 2 (inpatient, no longer requiring supplemental oxygen and no longer requiring care or grade 1 (hospital discharge) of the ordinal scale of the clinical state of the patient for 48 hours straight* and who has not had an adverse reaction of 3 or 4 or 5 according to the Criteria of Adverse Event Terminology (CTC-AE of the term in Common Terminology Criteria for Adverse Events). La eficacia y seguridad se evaluará a los 10 (±1) días de haber iniciado el tratamiento o al alta hospitalaria si ésta ocurre antes del día 10: número de pacientes que alcanzan el grado 2 (paciente hospitalizado, que ya no requiere oxígeno suplementario y ya no requiere atención médica continua) o grado 1 (alta hospitalaria) de la escala ordinal del estado clínico del paciente durante 48 horas seguidas* y que no haya presentado una reacción adversa de grado 3 ó 4 ó 5 según los Criterios de Terminología de Eventos Adversos (CTC-AE del término en inglés Common Terminology Criteria for Adverse Events).

Notes
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Declared number of arm (3.0) differs from found arms (2.0)

Phase
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Phase 2

Arms
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

[{"arm_notes": "", "treatment_id": 621, "treatment_name": "Icatibant", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]